AbbVie (NYSE:ABBV) Trading Up 1.8% – Here’s Why

AbbVie Inc. (NYSE:ABBV)’s share price was up 1.8% during trading on Monday . The stock traded as high as $213.94 and last traded at $213.1170. Approximately 7,222,637 shares changed hands during mid-day trading, a decline of 1% from the average daily volume of 7,309,602 shares. The stock had previously closed at $209.40.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Citigroup cut their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and increased their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. William Blair restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. UBS Group cut their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Finally, Morgan Stanley upped their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Stock Performance

The stock has a market cap of $376.83 billion, a PE ratio of 90.30, a P/E/G ratio of 0.73 and a beta of 0.34. The business has a 50 day moving average price of $221.96 and a two-hundred day moving average price of $224.71.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s revenue was up 10.0% on a year-over-year basis. During the same period last year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AbbVie

Large investors have recently modified their holdings of the stock. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the second quarter valued at $26,000. Chelsea Counsel Co. bought a new position in shares of AbbVie during the 3rd quarter worth $26,000. Litman Gregory Wealth Management LLC purchased a new stake in AbbVie in the 4th quarter worth about $28,000. Westend Capital Management LLC purchased a new stake in AbbVie in the 4th quarter worth about $29,000. Finally, Imprint Wealth LLC raised its stake in AbbVie by 56.3% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.